28.8 C
Vientiane
Wednesday, May 14, 2025
spot_img
Home Blog Page 449

New Book Challenges Traditional Hypertension Treatments: Case Study Reveals Breakthrough Approach

“Eradicating Hypertension” Explores How Oxygen Intake and Breathing Optimization Can Transform Blood Pressure Management


NEW YORK, USA – Media OutReach Newswire – 10 March 2025 – Hypertension remains one of the leading health concerns in the United States, affecting nearly half of all adults and contributing to heart disease, stroke, and kidney failure. However, a groundbreaking new book, Eradicating Hypertension: How Patient K Accidentally Got Rid of High Blood Pressure, is shifting the conversation by introducing a science-backed yet unconventional approach to blood pressure management—one that focuses on oxygen intake, breathing, and sleep therapy.

Source: POV Publish

Published by POV Publish, this book tells the true story of Patient K, a former hypertension patient who—despite decades of medication—found a surprising and effective solution by improving his breathing efficiency and oxygen levels using a BiPAP-assisted breathing device. His journey, documented with medical insights and real data, suggests that hypertension may not be a lifelong condition, but one that can be dramatically improved—or even reversed—with the right approach.

Unlike conventional hypertension treatments that primarily focus on medication and diet, Eradicating Hypertension explores the critical but overlooked connection between breathing, sleep quality, and cardiovascular health. The book explains how:

  • Oxygen intake plays a vital role in blood pressure regulation
  • Sleep apnea and low SpO2 (oxygen saturation) can silently worsen hypertension
  • Breathwork and assisted breathing devices (such as BiPAP) improve oxygen levels, reducing the need for medication
  • A holistic, patient-led approach can complement traditional treatments and provide new hope for millions

The release of Eradicating Hypertension comes at a critical time in the United States, where:

  • 47% of adults have high blood pressure, yet many are unaware of alternative solutions.
  • Sleep apnea affects an estimated 30 million Americans, but the link between low oxygen and hypertension remains under-discussed.
  • Breathwork and assisted breathing therapies are gaining traction in the U.S. wellness space, making this book a timely and valuable resource.

Estina Tan, Publisher at POV Publish, said: “For decades, hypertension has been treated as a condition that requires lifelong medication. But what if we’ve been overlooking something as simple as the way we breathe? Patient K’s journey shows that breathing optimization can dramatically impact blood pressure. This book aims to educate, empower, and change lives.”

Eradicating Hypertension is now available on Amazon, with an eBook, hardcover and paperback editions. Readers can also access additional resources by scanning the QR code in the book, including podcasts, illustrations, recommended products and extended chapters.
Hashtag: #POVPublish

The issuer is solely responsible for the content of this announcement.

ABOUT POV PUBLISH

POV Publish is an independent publishing house dedicated to bringing exclusive point-of-view stories to the world. We focus on blending real-life experiences, medical insights, and practical solutions to empower individuals to take control of their health.

ABOUT PATIENT K

Patient K is the author of Eradicating Hypertension, a book documenting a real-life transformation in blood pressure management. His journey, validated by medical experts, highlights the power of breathing, sleep optimization, and oxygen therapy in cardiovascular health.

Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC

CHENGDU, China, March 10, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) announced that the Company’s trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved for marketing by the National Medical Products Administration (NMPA) for the second indication which is for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy. This is the first TROP2 ADC drug approved for marketing in lung cancer globally. Compared with current standard of care, sac-TMT significantly extents the overall survival benefits of these patients.

The approval is based on a multi-center, randomized, controlled, pivotal study (OptiTROP-Lung03) that evaluates the efficacy and safety profile of sac-TMT monotherapy 5mg/kg every other week (Q2W) as an intravenous injection versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy (used sequentially or in combination). As demonstrated in a pre-specified interim analysis, sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) compared with docetaxel.

Sac-TMT is also the first ADC drug to demonstrate a statistically and clinically significant improvement in overall survival benefit versus standard of care in patients with EGFR-mutant NSCLC after failure of EGFR-TKI and platinum-based chemotherapy.

Previously, the NMPA has approved the marketing of sac-TMT in China for adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and accepted a supplemental new drug application (sNDA) seeking the approval of sac-TMT monotherapy for patients with EGFR-mutant NSCLC who have failed after EGFR-TKI therapy.

Currently, sac-TMT is fully deployed in the NSCLC field, and Merck Sharp & Dohme and the company are conducting a total of 10 registrational Phase Ⅲ clinical studies in NSCLC globally and in China, with the threads covering from the late backline to early postoperative adjuvant, including monotherapy and combination studies. Among them, a registrational Phase Ⅲ clinical study has been conducted in China in combination with osimertinib for the first-line treatment of locally advanced or metastatic NSCLC with EGFR mutations (OptiTROP-Lung07).

Dr. Michael Ge, CEO of Kelun-Biotech said, “We are very pleased that the second indication of the Company’s TROP2 ADC sacituzumab tirumotecan has been approved for marketing, which is exciting progress for us in the field of lung cancer. The successful approval of this new indication will help to address an unmet treatment need for patients with later-stage EGFRm NSCLC in China. Kelun-Biotech has always been committed to promoting innovation and leadership, and we look forward to continuing our research in the field of ADCs in partnership with MSD.”

About NSCLC

Lung cancer, the second most common cancer in the world, includes two main types of cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most common pathological type, accounting for about 80 to 85% of all lung cancers. The molecular typing of NSCLC patients in China is different from that of Western populations, and EGFR mutation is a common variant gene type, accounting for about 40 to 50% of lung adenocarcinoma patients in China. According to the 2024 Chinese Journal of Cancer Research (CSCO) guidelines, EGFR-TKIs are the preferred treatment for stage IV EGFR-mutant NSCLC.1 Platinum-containing chemotherapy is the main first-line chemotherapy regimen after resistance to EGFR-TKIs; and existing treatment regimens are ineffective in those who have failed EGFR-TKIs and platinum-containing chemotherapy. New drugs are urgently needed to improve patient survival.

About sac-TMT (佳泰莱®)

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan).

About Kelun-Biotech

Kelun-Biotech(6990.HK)is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel ADC projects in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

Reference

[1]. [Chinese Society of Clinical Oncology (CSCO) (2024)] Guidelines for the diagnosis and treatment of non-small cell lung cancer.

 

Mitsubishi Motors Canada Launches AI-Powered “Intelligent Companion” to Transform the 2025 Outlander Buying Experience

LONDON, ARMONK, N.Y. and MISSISSAUGA, ON, March 10, 2025 /PRNewswire/ — Mitsubishi Motor Sales of Canada announces an innovative AI-powered tool designed to transform the customer experience for the new Mitsubishi Outlander 2025. “The Intelligent Companion,” which launched on March 5, 2025, was created in collaboration with WongDoody (an Infosys company and IBM ecosystem partner) and leverages the IBM watsonx portfolio of AI products.


Leveraging IBM’s Granite model and trained on Mitsubishi Outlander 2025 data, this cutting-edge experience offers a personalized, interactive 3D visual guide to the vehicle’s features, enhancing customer engagement during the purchasing decision.

As a challenger brand, Mitsubishi Motors Canada is taking a focused approach to AI, investing in tools that can deliver real value to customers. “The Intelligent Companion” is the result of a first-time collaboration between Mitsubishi Motors Canada, WongDoody, and IBM.

This advanced tool offers a deep dive into AI-driven interactions, allowing users to explore the new Outlander in a real-world, Mitsubishi-branded environment. Developed by WongDoody, the 3D visualization within “The Intelligent Companion” showcases the vehicle’s features in an engaging and interactive way.

Unlike traditional brochure-ware, pre-set vehicle tours and legacy chatbots, “The Intelligent Companion” adapts to each customer, creating a personalized journey from vehicle-curious to vehicle-owner. It is built with IBM watsonx Orchestrate, a generative AI and automation solution for building, deploying and managing AI agents and assistants, and watsonx.ai, an integrated, end-to-end AI development studio. These tools enable it to handle large amounts of data and is designed to provide responses that feel natural and conversational.

Trained and rigorously tested with Canadian target audiences to ensure it addresses niche questions and use cases with incredible relevance and value, customers can ask any questions they have about the vehicle specific to their needs, making it a versatile, relevant, and engaging tool. Leveraging the innovative AI and automation capabilities of watsonx, “The Intelligent Companion” gives customers personalized guidance within a next-generation automotive buying experience.

Developed with a global team of AI and experience experts, the project moved from initial conversations to a proof of concept in just four weeks and was designed by WongDoody in collaboration with IBM Client Engineering and launched in market within an impressive twelve weeks—a testament to the speed and efficiency of WongDoody’s expertise and creative efficiency, alongside the flexibility of the watsonx technology.

Steve Carter, Marketing Director, Mitsubishi Motors Canada: “The Intelligent Companion” represents a major leap forward in customer engagement, offering a tailored experience that highlights the best features of the Mitsubishi Outlander 2025. Working with WongDoody and IBM has been an incredible collaboration, and we’re truly impressed by how quickly this innovation came to life. This tool perfectly aligns with our commitment to leveraging cutting-edge technology to enhance customer satisfaction and drive innovation across our brand.”

Ralf Gehrig, Global Chief Experience Officer, WongDoody: “Bringing this project to life at such speed and scale is a testament to the power of AI and global collaboration. With expertise from across the world, we combined technology and creative problem-solving to create something truly innovative in record time. This project proves that when the right minds and technology come together, the possibilities are endless.”

“With the watsonx portfolio, clients can swiftly and efficiently integrate generative AI into their operations, leveraging their own enterprise data to help enrich customer experiences and boost productivity for the enterprise. Solutions like watsonx Orchestrate and watsonx.ai are designed to scale and accelerate AI impact, empowering businesses to transform how they go to market and become AI-first organizations,” added Matt Sanchez, VP of product, watsonx Orchestrate at IBM.

About Mitsubishi Motor Sales of Canada, Inc.

Mitsubishi Motor Sales of Canada (MMSCAN) is the sales, service, parts and marketing arm for Japan’s Mitsubishi Motors. The 2025 product range includes the RVR subcompact crossover, Eclipse Cross compact sport utility and Outlander/Outlander PHEV compact sport utility. MMSCAN supports its 97 dealerships with a head office team and parts distribution centre, both located in Mississauga, Ontario. Established in 2002, MMSCAN and its dealerships employ more than 2,100 people in communities large and small.

For more information on Mitsubishi vehicles in Canada, please visit mitsubishi-motors-pr.ca 

About IBM:

IBM (NYSE: IBM) is a leading provider of global hybrid cloud, artificial intelligence, and consulting expertise. We help clients in over 175 countries harness insights from their data, optimize business processes, reduce costs and gain a competitive advantage in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on the IBM hybrid cloud platform and Red Hat OpenShift to achieve their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in artificial intelligence, quantum computing, industry-specific cloud solutions and consulting offer open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, accountability, inclusion and service. Visit www.ibm.com for more information.

IBM, the IBM logo, ibm.com and other marks belonging to IBM. IBM products and services are trademarks of the International Business Machines Corp., registered in many jurisdictions worldwide. A current list of IBM trademarks is available on the web at “Copyright and trademark information” at www.ibm.com/legal/copytrade.shtml.

About WongDoody:

WongDoody is the creative and technology agency from Infosys that creates intelligent marketing and experiences helping unlock what’s next for people and brands. With 22 studios and 2000+ employees around the globe, we serve clients in more than 55 countries with radically relevant human-centered creativity that solves business problems and transforms businesses through digital marketing that unlocks future potential with AI-driven marketing, data-backed strategies, intelligent products, services and platforms, virtual and augmented reality, digital twins, and next-gen AI content that people love. For more information https://www.wongdoody.com/ / 

Contacts:

Sabreena Dean, WongDoody
sabreena.dean@wongdoody.com

Clare Chachere, IBM
clare.chachere@ibm.com

IBM Corporation logo.
IBM Corporation logo.

GIGABYTE Elevates Immersive Content with AI and XR at SXSW 2025

Experience the Future of AI-Powered Creativity! GIGABYTE AI PCs Lead You to Explore New Frontiers

TAIPEI, March 10, 2025 /PRNewswire/ — GIGABYTE, a global leader in high-performance computing, partners with the Taiwan Creative Content Agency (TAICCA) at SXSW 2025 XR Lounge, unveiling cutting-edge AI-driven solutions that push the boundaries of immersive content creation. Featuring advanced AI computing technology, GIGABYTE presents two groundbreaking experiences: VS AI Street Fighting Arcade and 4K 360 VR Video Editing Workflow, showcasing the capabilities of GIGABYTE AI PCs and their role in shaping the future of creative applications.

GIGABYTE Elevates Immersive Content with AI and XR at SXSW 2025
GIGABYTE Elevates Immersive Content with AI and XR at SXSW 2025

Game On: AI-Powered Real-Time Competition

GIGABYTE’s VS AI Arcade offers an interactive 1v1 gaming challenge, where players generate unique AI-driven artwork using text-to-image prompts in real time. Competitors bring their creativity to life with GIGABYTE AI PCs, powered by the Z790 AORUS MASTER motherboard and GeForce RTX 40 Series GPUs. The VS AI Arcade highlights GIGABYTE’s high-performance hardware in AI-enhanced gaming while showcasing how AI accelerates real-time content creation, transforming the gaming experience into an innovative and artistic challenge.

Next-Level AI Computing for Immersive Content Creation

For VR professionals, GIGABYTE introduces an 8K VR video editing workflow, featuring renowned creators Hugh Hou and Keeley Turner. Utilizing the TRX50 AERO D motherboard and GeForce RTX 4090 GAMING OC, this showcase demonstrates the next evolution of AI-powered video production, delivering seamless workflows and expanding creative possibilities in immersive media.

Key Highlights:

  • AI-Driven Workflow – Transforming 360 VR video editing with AI-powered enhancements.
  • Topaz Video AI Upscaling – Elevating lower-resolution footage to 8K clarity through AI-based video upscaling.
  • Real-Time Editing in Adobe Premiere Pro – Achieve seamless previewing and upscaling, powered by GIGABYTE AI PC performance.
  • Immersive 360 VR Experience – Experience high-definition VR storytelling, enhanced by AI-driven workflows.

Join Us at SXSW 2025

As AI continues to revolutionize creative industries, GIGABYTE remains at the forefront, delivering cutting-edge hardware solutions that redefine gaming, content creation, and immersive experiences.

Visit us at SXSW 2025 XR Lounge, located in the “Sunflower” Ballroom at the Fairmont Austin, to explore how GIGABYTE AI PCs are shaping the next generation of AI-driven digital storytelling, immersive interaction, and creative workflows.

Prepare for Blackouts with BLUETTI Solar Battery Backup Solutions

SYDNEY, March 10, 2025 /PRNewswire/ — More power outages are expected in Australia as rare Tropical Cyclone Alfred bears down on the country’s east coast, bringing destructive winds and flooding. About 4,000 homes have already lost power due to downed power lines.

BLUETTI
BLUETTI

For many, blackouts mean spoiled food, loss of internet, and pitch-black nights. However, those who prepare ahead, like Craig Payne from NSW, can navigate outages effortlessly.

When a severe storm cut power to his home for 16 hours, he relied on his BLUETTI AC200PL portable power station with additional battery modules. He also used solar panels to recharge the system throughout the outage.

Solar-powered generators like BLUETTI’s offer a reliable, clean, and quiet backup power solution for extreme weather or outdoor adventures. They harness solar energy for sustainable recharging, perfect for long-term blackouts. Here are some top choices for Australian homes.

BLUETTI Portable Solar Generators for Short-Term Outage Backup

If the grid is down for a few hours, a portable power station like BLUETTI AC180 is what a home needs for essential charging. It outputs 1,800W power to run most devices like fans, fridges, lights, and coffee makers. With its 1,152Wh battery, it keeps groceries fresh in the fridge for over 7 hours.

A more powerful option is the 2,600W BLUETTI Elite 200 V2-sufficient for operating ovens and even air conditioners. Its 2,073Wh battery can run a home fridge for 14 hours. Built with automotive-grade LiFePO4 cells, it’s expected to last for over 16 years with daily use. Both models support fast solar recharging to keep homes powered off-grid.

BLUETTI Modular Solar Battery System for Extended Power Outages

For longer outages, the BLUETTI AC500+ 2xB300K combo delivers robust home backup. With a 5,000W output and 5,529Wh capacity, it can power an 8100BTU air conditioner for 2 hours. As it’s modular, homeowners can scale it to a maximum of 16,588Wh with extra B300K batteries. Fast charging via mains (5,000W) or solar (3,000W) reduces dependency on the grid and helps lower electricity costs.

About BLUETTI

As a technology pioneer in clean energy, BLUETTI provides affordable clean energy storage solutions for both indoor and outdoor use. Through initiatives like the LAAF (Lighting An African Family) program, BLUETTI aims to power 1 million African families in off-grid areas. Focusing on innovation and customer needs, BLUETTI has become a trusted industry leader in over 110 countries and regions.

 

Yum China Appoints Adrian Ding as Chief Financial Officer

SHANGHAI, March 10, 2025 /PRNewswire/ — Yum China Holdings, Inc. (the “Company” or “Yum China“) (NYSE: YUMC and HKEX: 9987) announced that after a thorough search process, Adrian Ding has been appointed as Chief Financial Officer, effective on March 6, 2025. Adrian has been serving as Acting Chief Financial Officer since October 2024.

“We are delighted to announce Adrian’s appointment as our CFO. Over the last five months, he has made significant contributions, proving himself as the ideal candidate to serve as the Chief Financial Officer of Yum China. He has effectively led the finance team, strengthened our engagement with stakeholders, including the capital markets, and played a pivotal role in building Yum China’s growth momentum,” said Joey Wat, CEO of Yum China. “With his deep understanding of our strategies and strong business acumen, I am confident that Adrian will continue to play an instrumental role in driving our RGM 2.0 strategy. I look forward to partnering closely with him as we enter another exciting phase of growth and development.”

Adrian Ding joined the Company in March 2019 as Vice President of Corporate Finance and served as Chief Investment Officer from February 2020 to March 2025.  Over the past six years, Adrian has led multiple investment and capital markets projects to enhance the Company’s portfolio and organizational strengths, including the acquisitions of KFC joint venture stakes, and strategic investments in the supply chain, technology, and other strategic areas. He also played a critical role in driving Yum China’s listing on the Hong Kong Stock Exchange. Additionally, Adrian served as General Manager of the Company’s Lavazza joint venture from March 2022 to December 2024. He was instrumental in establishing and building the Lavazza business in China.

Prior to joining the Company, Adrian worked for Alibaba Group Holding Limited from 2018 to early 2019, responsible for strategic investments in the technology and media sectors. Before that, he gained extensive experience in investment banking, advising clients on a number of capital markets and M&A projects. Adrian worked at UBS AG as a Director in Investment Banking and previously held roles at Morgan Stanley and Citigroup Global Markets Asia Limited. Adrian currently serves as a director of Fujian Sunner Development Co., Ltd. (Shenzhen Stock Exchange: 002299). He obtained a Master’s degree in Business Administration (MBA) from Columbia Business School, and a Bachelor’s degree in Quantitative Finance from Hong Kong University of Science and Technology.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by the use of forward-looking words such as “expect,” “expectation,” “believe,” “anticipate,” “may,” “could,” “intend,” “belief,” “plan,” “estimate,” “target,” “predict,” “project,” “likely,” “will,” “continue,” “should,” “forecast,” “outlook,” “commit” or similar terminology. These statements are based on current estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable under the circumstances, but there can be no assurance that such estimates and assumptions will prove to be correct. Forward-looking statements are not guarantees of performance and are inherently subject to known and unknown risks and uncertainties that are difficult to predict and could cause our actual results or events to differ materially from those indicated by those statements. We cannot assure you that any of our expectations, estimates or assumptions will be achieved. The forward-looking statements included in this press release are only made as of the date of this press release, and we disclaim any obligation to publicly update any forward-looking statement to reflect subsequent events or circumstances, except as required by law. Numerous factors could cause our actual results or events to differ materially from those expressed or implied by forward-looking statements. In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any such forward-looking statements. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty. You should consult our filings with the Securities and Exchange Commission (including the information set forth under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q) for additional detail about factors that could affect our financial and other results.

About Yum China Holdings, Inc.

Yum China is the largest restaurant company in China with a mission to make every life taste beautiful. The Company operates over 16,000 restaurants under six brands across over 2,200 cities in China. KFC and Pizza Hut are the leading brands in the quick-service and casual dining restaurant spaces in China, respectively. In addition, Yum China has partnered with Lavazza to develop the Lavazza coffee concept in China. Little Sheep and Huang Ji Huang specialize in Chinese cuisine. Taco Bell offers innovative Mexican-inspired food. Yum China has a world-class, digitalized supply chain, which includes an extensive network of logistics centers nationwide and an in-house supply chain management system. Its strong digital capabilities and loyalty program enable the Company to reach customers faster and serve them better. Yum China is a Fortune 500 company with the vision to be the world’s most innovative pioneer in the restaurant industry. For more information, please visit http://ir.yumchina.com.

Contacts

Investor Relations Contact:

Tel: +86 21 2407 7556

IR@YumChina.com

 

Media Contact:

Tel: +86 21 2407 8288 / +852 2267 5807

Media@YumChina.com

 

XCMG Certified Pre-Owned Crawler Cranes Deployed in Southeast Asia to Support Large-Scale Infrastructure Projects

NAYPYIDAW, Myanmar, March 10, 2025 /PRNewswire/ — XCMG Machinery (“XCMG”, SHE: 000425), a global leader in construction equipment manufacturing, has successfully delivered a batch of XCMG Certified Pre-Owned Crawler Cranes, models XGC85 and XGC55, to support major infrastructure projects in Southeast Asia. This milestone underscores XCMG’s commitment to advancing sustainable development and promoting the circular economy in the global construction industry.

XCMG Certified Pre-Owned Crawler Cranes Deployed in Southeast Asia to Support Large-Scale Infrastructure Projects
XCMG Certified Pre-Owned Crawler Cranes Deployed in Southeast Asia to Support Large-Scale Infrastructure Projects

The pre-owned crawler cranes, previously in service for 4 to 7 years, have undergone XCMG’s rigorous certification and refurbishment process. This includes comprehensive inspections and maintenance of key components such as booms, pins, cylinders, and interiors, with necessary parts replaced.

Additionally, the hydraulic system, travel, and slewing functions were thoroughly tested and recalibrated to ensure optimal performance. The refurbishment was completed with deep cleaning and repainting, restoring the cranes to near-new condition. When maintained according to XCMG’s guidelines, these machines are expected to operate efficiently for another 5 to 7 years.

The certificated used XGC85 crawler crane offers:

  • Reliable Hydraulic Components – Ensuring stability and efficiency in high-load, continuous operations.
  • Fast-Release Drum with Disc Brake – Enhancing work efficiency, with one-touch switching between main and auxiliary hook conditions for improved operational convenience.
  • Dual-Mode Operation Interface – Adapting to diverse working environments, while the 850mm wide track shoes enhance durability and stability in construction applications.

The used XGC55 crawler crane is designed for superior transportability and efficiency:

  • Integrated Transport Design – Significantly reducing transportation and assembly costs.
  • Innovative Self-Erecting A-Frame Technology – Enabling faster and more efficient crane assembly.
  • Optimized Hydraulic System – Featuring an integrated design that reduces failure points and enhances maintenance accessibility.
  • Modular and Universal Design – Lowering procurement, transportation, and maintenance costs, while also allowing seamless switching between main and auxiliary hook conditions for greater operational efficiency.

This marks XCMG’s first delivery of used equipment to the Southeast Asian market following the establishment of its Used Equipment Certification program in 2024. This initiative is a key step in XCMG’s commitment to promoting sustainable development in the industry. The Used Equipment Certification program, launched by XCMG, aims to extend the lifecycle of construction equipment by providing reliable certification for second-hand machinery, ensuring high quality and environmental sustainability.

Looking ahead, XCMG aims to sell 70 units of certified pre-owned equipment in 2025, further promoting the principles of the circular economy and sustainable development in the construction industry.

 

Hon Hai Research Institute Launches Traditional Chinese LLM With Reasoning Capabilities

First version by AI Research Center performs well in mathematics and reasoning

TAIPEI, March 10, 2025 /PRNewswire/ — Hon Hai Research Institute announced today the launch of the first Traditional Chinese Large Language Model (LLM), setting another milestone in the development of Taiwan’s AI technology with a more efficient and lower-cost model training method completed in just four weeks.

The institute, which is backed by Hon Hai Technology Group (“Foxconn”) (TWSE:2317), the world’s largest electronics manufacturer and leading technological solutions provider, said the LLM – code named FoxBrain – will be open sourced and shared publicly in the future. It was originally designed for applications used in the Group’s internal systems, covering functions such as data analysis, decision support, document collaboration, mathematics, reasoning and problem solving, and code generation.

FoxBrain not only demonstrates powerful comprehension and reasoning capabilities but is also optimized for Taiwanese users’ language style, showing excellent performance in mathematical and logical reasoning tests.

“In recent months, the deepening of reasoning capabilities and the efficient use of GPUs have gradually become the mainstream development in the field of AI. Our FoxBrain model adopted a very efficient training strategy, focusing on optimizing the training process rather than blindly accumulating computing power,” said Dr. Yung-Hui Li, Director of the Artificial Intelligence Research Center at Hon Hai Research Institute. “Through carefully designed training methods and resource optimization, we have successfully built a local AI model with powerful reasoning capabilities.”

The FoxBrain training process was powered by 120 NVIDIA H100 GPUs, scaled with NVIDIA Quantum-2 InfiniBand networking, and finished in just about four weeks. Compared with inference models recently launched in the market, the more efficient and lower-cost model training method sets a new milestone for the development of Taiwan’s AI technology.

FoxBrain is based on the Meta Llama 3.1 architecture with 70B parameters. In most categories among TMMLU+ test dataset, it outperforms Llama-3-Taiwan-70B of the same scale, particularly exceling in mathematics and logical reasoning (For TMMLU+ benchmark of FoxBrain, please refer to Fig.1). The following are the technical specifications and training strategies for FoxBrain:

  • Established data augmentation methods and quality assessment for 24 topic categories through proprietary technology, generating 98B tokens of high-quality pre-training data for Traditional Chinese
  • Context window length: 128 K tokens
  • Utilized 120 NVIDIA H100 GPUs for training, with total computational cost of 2,688 GPU days
  • Employed multi-node parallel training architecture to ensure high performance and stability
  • Used a unique Adaptive Reasoning Reflection technique to train the model in autonomous reasoning

Fig. 1: TMMLU+ benchmark results of FoxBrain, Meta-Llama-3.1-70B and Taiwan-Llama-70B
Fig. 1: TMMLU+ benchmark results of FoxBrain, Meta-Llama-3.1-70B and Taiwan-Llama-70B

In test results, FoxBrain showed comprehensive improvements in mathematics compared to the base Meta Llama 3.1 model. It achieved significant progress in mathematical tests compared to Taiwan Llama, currently the best Traditional Chinese large model, and surpassed Meta’s current models of the same class in mathematical reasoning ability. While there is still a slight gap with DeepSeek’s distillation model, its performance is already very close to world-leading standards.

FoxBrain’s development – from data collection, cleaning and augmentation, to Continual Pre-Training, Supervised Finetuning, RLAIF, and Adaptive Reasoning Reflection – was accomplished step by step through independent research, ultimately achieving benefits approaching world-class AI models despite limited computational resources. This large language model research demonstrates that Taiwan’s technology talent can compete with international counterparts in the AI model field.

Although FoxBrain was originally designed for internal group applications, in the future, the Group will continue to collaborate with technology partners to expand FoxBrain’s applications, share its open-source information, and promote AI in manufacturing, supply chain management, and intelligent decision-making.

During model training, NVIDIA provided support through the Taipei-1 Supercomputer and technical consultation, enabling Hon Hai Research Institute to successfully complete the model pre-training with NVIDIA NeMo. FoxBrain will also become an important engine to drive the upgrade of Foxconn’s three major platforms: Smart Manufacturing. Smart EV. Smart City.

The results of FoxBrain is scheduled to be shared for the first time at a major conference during NVIDIA GTC 2025 Session Talk “From Open Source to Frontier AI: Build, Customize, and Extend Foundation Models” on March 20.

About Hon Hai Research Institute

The institute has five research centers. Each center has an average of 40 high technology R&D professionals, all of whom are focused on the research and development of new technologies, the strengthening of Foxconn’s technology and product innovation pipeline, efforts to support the Group’s transformation from “brawn” to “brains”, and the enhancement of the competitiveness of Foxconn’s “3+3” strategy.

About Foxconn here.